Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination With Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer

Trial Profile

A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination With Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs Capivasertib (Primary) ; Danvatirsen (Primary) ; Durvalumab (Primary) ; Oleclumab (Primary) ; Paclitaxel (Primary) ; Selumetinib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms BEGONIA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 Jan 2019 Planned End Date changed from 4 Jul 2022 to 24 Jun 2022.
    • 18 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 19 Dec 2018 Planned End Date changed from 3 Jun 2022 to 4 Jul 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top